Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 2016

View Archived Issues

EMA issues positive opinion on the MAA for SomaKit TOC

Heidelberg Pharma signs option agreement with the Max Delbruck Center for BCMA antibodies

Enrollment open in phase I trial of HS-10241 in solid tumors

Grant supports Garvan Institute of Medical Research's purchase of Chromium Genome Solution

Shanghai Institute Materia Medica patents anticancer agents

Phase II study of CMV vaccine ASP-0113 in kidney transplant patients does not meet primary endpoint

FDA approves Kyleena for prevention of pregnancy for up to 5 years

KemPharm submits IND application to commence clinical trials of KP-415

Eli Lilly discloses GPR142 agonists

Bristol-Myers Squibb and Rigel Pharmaceuticals describe TGF-beta1 inhibitors

PRIDE-HD study demonstrates statistically significant impact on disease progression at 52 weeks

Evgen's SFX-01 shows promise in preclinical MS model

SUSTAIN-6 finds reduced cardiovascular outcomes with semaglutide in type 2 diabetes patients

Prexton Therapeutics completes phase I study of lead compound for Parkinson's disease

Siponimod reduces the risk of MS disability progression

ARN-6039 safe in phase I trial

FDA grants accelerated approval to Exondys 51 for Duchenne muscular dystrophy

XOMA updates status of phase II trials of XOMA-358 in severe hypoglycemia

Testing of IRX-4204 in preclinical MS model shows promising results

NovaBay Pharmaceuticals' Auriclosene Irrigating Solution shows positive results in phase IIb study

FDA grants fast track designation to SELLAS' galinpepimut-S

PSP/reg shows promise as an assistive biomarker for the diagnosis of DN

GUB09-145 exerts marked effects on HbA1c, body weight and glucose homestasis in mice

FDA awards fast track status to Aerosurf for RDS

BioArctic and AbbVie collaborate on Parkinson's disease

Cantargia outlines plans for CAN-04 development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...